NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020.
Category: Business
Resumen: RIBOMIC anuncia la primera inyección en el ensayo clínico de fase 2 de RMB-007 (estudio TOFU) en sujetos que sufren degeneración macular húmeda asociada con la edad
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc., empresa farmacéutica de etapa clínica especializada en terapias con aptámeros y que cotiza en el mercado de Empresas Madres de la Bolsa de Tokio (Número de código: 4591), ha anunciado hoy que se le ha administrado…
RIBOMIC annonce la première injection dans l’essai clinique de phase 2 portant sur le RBM-007 (Étude TOFU) chez des sujets atteints de dégénérescence maculaire liée à l’âge, dans sa forme humide
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., une société pharmaceutique de stade clinique, spécialisée dans les produits thérapeutiques à base d’aptamères, et cotée au Mothers Market de la Bourse de Tokyo (numéro de code : 4591), a annoncé aujourd’hui qu’un …
RIBOMIC kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc. ist ein auf Aptamer-Therapeutika spezialisiertes Pharmaunternehmen im klinischen Segment und wird am Mothers Market der Tokioter Börse gehandelt (Codenummer: 4591). Das Unternehmen gab heute bekannt, dass der erste…
Global Glass Lens Market 2018-2022 | Availability of Products Through Online Distribution Channels to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlassLensMarket–The global glass lens market is expected to post a CAGR of around 4% during 2018-2022.
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration
TOKYO–(BUSINESS WIRE)–RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration
Myopia Management Focus of Pipeline Expansion for Leo Lens Pharma
SAN DIEGO–(BUSINESS WIRE)–Myopia Management Focus of Pipeline Expansion for Leo Lens Pharma
National Vision Donates More Than 8,100 Pairs of Eyeglasses to Kids in Need
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, today announced that it donated more than 8,100 pairs of free prescription eye…
Fort du succès de la première édition, les HealthTech Innovation Days (HTID®) se tiendront les 22 et 23 juin 2020 à Paris
PARIS–(BUSINESS WIRE)– #biotech–SAVE THE DATE – Fort du succès de la première édition, les HealthTech Innovation Days (HTID®) se tiendront les 22 et 23 juin 2020 à Paris.
Driven by Its Successful Debut, the Second Annual International HealthTech Innovation Days Will Take Place in Paris on June 22nd & 23rd
PARIS–(BUSINESS WIRE)– #biotech–Launched in 2019 by France Biotech and driven by its successful debut, the second annual HealthTech Innovation Days (HTID®) will be held in Paris on June 22nd and June 23rd, 2020. The pre-eminent industry event brings…
FDA Grants Priority Review to Genentech’s Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (s…
Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from …
Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
GENEVA–(BUSINESS WIRE)–Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
GENEVA–(BUSINESS WIRE)–Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, after the close of the U.S. financial markets. ACADIA’s mana…
Workiva unterstützt Alcon bei der Skalierung von Rechnungslegung, Unternehmensrisikomanagement und Einhaltung der SOX-Vorgaben auf weltweiter Ebene
AMES, Iowa–(BUSINESS WIRE)–Workiva (NYSE:WK), Anbieter der weltweit führenden vernetzten Berichts- und Compliance-Plattform, gab heute bekannt, dass Alcon (NYSE:ALC) die Workiva-Plattform zum Aufbau und zur Skalierung der weltweiten Prozesse für Rech…
Workiva Helps Alcon Scale Global Audit, Enterprise Risk Management and SOX Compliance
AMES, Iowa–(BUSINESS WIRE)—- $WK #100BestCos–Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, today announced that Alcon (NYSE:ALC) is using the Workiva platform to build and scale its global audit, En…
Midwest Vision Partners Announces Partnership With Rosenbaum Eye & Laser Center
CHICAGO & LANSING, Mich.–(BUSINESS WIRE)–Midwest Vision Partners (“MVP”) is pleased to announce its partnership with Rosenbaum Eye & Laser Center (“RELC”) and its vision correction center, Michigan Laser Eye Associates (“MLEA”). This represents M…
Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that Kevin Peters, M.D., Aerpio’s Ch…
PhotoniCare's TOMi Scope takes Top Prize at SPIE and Photonics Media Prism Awards
CHAMPAIGN, Ill.–(BUSINESS WIRE)–PhotoniCare’s TOMi Scope takes Top Prize at SPIE and Photonics Media Prism Awards